drug_type
RELEVANT_DRUG
intervention_type
Biological
drug_description
Humanized anti-HER2 monoclonal antibody that binds domain II of ERBB2, blocking HER2 dimerization with HER3/EGFR and downstream signaling.
nci_thesaurus_concept_id
C38692
nci_thesaurus_preferred_term
Pertuzumab
nci_thesaurus_definition
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)
drug_mesh_term
Pertuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting HER2 (ERBB2) domain II, preventing HER2 heterodimerization (especially with HER3/EGFR), thereby inhibiting downstream PI3K/AKT and MAPK signaling; can also mediate antibody-dependent cellular cytotoxicity, resulting in growth arrest and apoptosis of HER2-positive tumor cells.
drug_name
Pertuzumab
nct_id_drug_ref
NCT06162559